Brand Name
ZYFLO
Generic Name
Zileuton
View Brand Information FDA approval date: December 06, 1996
Classification: 5-Lipoxygenase Inhibitor
Form: Tablet
What is ZYFLO (Zileuton)?
Zileuton extended-release tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Zileuton extended-release tablets are not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with zileuton extended-release tablets can be continued during acute exacerbations of asthma. Zileuton extended-release tablets are a leukotriene synthesis inhibitor indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Do not use zileuton extended-release tablets to treat an acute asthma attack.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment